Vertex Pharmaceuticals Stock Fundamentals

VRTX Stock  USD 397.48  0.22  0.06%   
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vertex Pharmaceuticals Company Return On Equity Analysis

Vertex Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Vertex Pharmaceuticals Return On Equity

    
  0.23  
Most of Vertex Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Vertex Total Stockholder Equity

Total Stockholder Equity

18.46 Billion

At this time, Vertex Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year.
Based on the latest financial disclosure, Vertex Pharmaceuticals has a Return On Equity of 0.2299. This is 100.96% lower than that of the Biotechnology sector and 100.63% lower than that of the Health Care industry. The return on equity for all United States stocks is 174.16% lower than that of the firm.

Vertex Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vertex Pharmaceuticals competition to find correlations between indicators driving Vertex Pharmaceuticals's intrinsic value. More Info.
Vertex Pharmaceuticals is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies reporting about  0.57  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Vertex Pharmaceuticals is roughly  1.75 . At this time, Vertex Pharmaceuticals' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Vertex Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vertex Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vertex Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Vertex Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.
Vertex Pharmaceuticals is currently under evaluation in return on equity category among related companies.

Vertex Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Vertex Fundamentals

About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue170.3 M118.8 M
Total Revenue9.8 B10.3 B
Cost Of Revenue1.3 B1.3 B
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue 0.00  0.00 
Research And Ddevelopement To Revenue 0.38  0.36 
Capex To Revenue(0.03)(0.03)
Revenue Per Share 38.18  40.09 
Ebit Per Revenue 0.38  0.40 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.181
Earnings Share
13.87
Revenue Per Share
38.297
Quarterly Revenue Growth
0.093
Return On Assets
0.1317
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.